AKT1 and colorectal carcinoma: Increasing studies have demonstrated that DCLK1 can promote EMT through downregulating several key tumor suppressor microRNAs and activating NF‐κB through the PI3K/Akt pathway [44, 45], indicating targeting DCLK1 may be a therapeutic option for hampering CRC metastasis.